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ABSTRACT
Background: Hepatocellular carcinoma (HCC) remains a major problem throughout the world, especially 
in diagnostic and therapeutic management. Previous studies stated that alpha-1 acid glycoprotein (AAG) was 
a potensial biomarker in diagnostic of HCC. This study assessed the best cut-off value of AAG as a diagnostic 
biomarker of HCC with liver cirrhosis. 
Method: This was a cross-sectional, diagnostic study, conducted from January to October 2013 in Cipto 
Mangunkusumo Hospital. The subjects were HCC with liver cirrhosis patients and as control were liver cirrhosis 
patients. Abdominal ultrasonography (USG), abdominal 3 phase contrast computerized tomography (CT) 
scan, and liver biopsy, if necessary, were done. All patients were having AAG examination, then the result was 
analyzed using receiver operating characteristic (ROC) curve and assessment of some cut-off values was done.
Results: There were 25 HCC with liver cirrhosis patients and 37 liver cirrhosis patients as control included 
in this study. HCC with liver cirrhosis patients were 92% male and 8% were female, over 50 years old (72%). 
HBV infection was the most common etiology and most of the patients had multiple nodules in the liver (80%). 
ROC curve showed the area under the curve (AUC) was 81.44%. 
Conclusion: The best cut-off value of AAG to be aware of HCC with liver cirrhosis was 61 mg/dL and as a 
diagnostic was 136 mg/dL.
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ABSTRAK
Latar belakang: Karsinoma hepatoselular (KHS) masih menjadi masalah utama di seluruh dunia, terutama 
dalam hal diagnosis dan penatalaksanaannya. Penelitian terdahulu menyatakan bahwa alfa-1 asam glikoprotein 
(AAG) merupakan biomarker potensial dalam mendiagnosis KHS. Penelitian ini mengkaji nilai titik potong 
terbaik AAG sebagai biomarker diagnostik KHS dengan sirosis hati.
Metode: Penelitian ini merupakan studi diagnostik dengan desain potong lintang yang dilakukan dari bulan 
Januari hingga Oktober 2013 di Rumah Sakit Cipto Mangunkusumo, Jakarta. Subjek penelitian ini adalah 
pasien KHS dengan sirosis hati, sebagai kontrol pasien sirosis hati saja. Pemeriksaan pencitraan yang dilakukan 
????????????????????????????????????computerized tomography (CT) scan abdomen dengan kontras 3 fase, 
dan bila perlu dilakukan biopsi hati. Pemeriksaan AAG dilakukan pada semua pasien, kemudian dianalisis 
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dengan receiver operating characteristic (ROC) dan dikaji beberapa titik potongnya.
Hasil: Sebanyak 25 pasien KHS dengan sirosis hati dan 37 pasien sirosis hati sebagai kontrol terlibat dalam 
penelitian ini. Dari seluruh pasien KHS dengan sirosis hati, 92% laki-laki, 8% perempuan, sebagian besar 
berusia diatas 50 tahun (72%). Etiologi terbanyak adalah infeksi HBV (56%) dan sebagian besar dijumpai 
nodul multipel (80%). Dengan menggunakan ROC, didapatkan area under the curve (AUC) sebesar 81,44%. 
Simpulan: Titik potong terbaik AAG untuk mulai mewaspadai KHS dengan sirosis hati adalah 61 mg/dL 
dan untuk diagnostik adalah 136 mg/dL.
Kata kunci: karsinoma hepatoselular, alfa 1-asam glikoprotein, nilai titik potong
INTRODUCTION
Hepatocelular carcinoma (HCC) is one of the 
most common malignancies in the world. At present, 
?????????????????????? ????????????????????????1,2,3 
According to the World Health Organization (WHO) 
in 2002, it was around 564,000 new cases of HCC per 
year globally.4 In 2010, 650,000 people in the world 
died every year due to HCC.3 
HCC is the top three causes of cancer death in 
????????????????????????????????????????????????????
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections. 5 Some countries such as China and Taiwan, 
are still having high incidence with male predilection 
although doing immunization program. Moreover, 
there was high incidence of HBV-related HCC among 
???????????? ?????????? ???????????? ??????????? ????
Taiwan) in Australia.6 In Indonesia, some centers in 
big cities such as Jakarta, Surabaya, or Bandung have 
their own HCC prevalence data; however national 
HCC prevalence data has not been available yet. Out-
patient visit data in hepatolobiliary clinic, Department 
of Internal Medicine, Cipto Mangunkusumo Hospital 
in 2001 showed prevalence of HCC in out-patient visit 
was 7.3% (60 from 819 visits) in a year and most of 
them are in terminal stage.7
According to Asia Pacific Association for the 
Study of the Liver (APASL) 2010 guidelines, we 
need abdominal ultrasonography (USG) and 3 phases 
contrast abdominal computerized tomography (CT) 
examinations to diagnose HCC.8 In daily clinical 
practice, the increase of alpha feto-protein (AFP) to 
greater than 200 ng/mL also supports the diagnosis 
of HCC. If both imaging and AFP examination are 
uncertain, we need to do liver biopsy to establish the 
diagnosis of HCC. APASL 2010 guidelines cannot 
be widely applied, especially in Indonesia. It is just 
suitable for big centers having CT scan machine and 
radiologists. Also, it is not affordable in low income 
society due to the high cost. To date, AFP and other 
diagnostic modalities (abdominal USG, CT scan, etc) 
are still being widely used as biomarker to support 
diagnostic surveillance and prognostic indicator in 
HCC patients.9-13 However, some studies showed the 
accuracy of AFP in diagnosing HCC was not as good 
as Des-gamma carboxyprothrombin (DCP) dan Lens 
culinaris agglutinin-reaction of alpha feto-protein 
(AFP L-3).14,15 Researchers are looking for better HCC 
diagnostical biomarker. There were some potential 
biomarkers such as alpha-1 acid glycoprotein (AAG). 
A study by Chio LF and Oon CJ, AAG increased 
in 80% HCC patients, higher than cirrhotic patients 
(20%) and chronic hepatitis patients (5.7%).16 AAG 
had good sensitivity and accuracy in diagnosing 
HCC. The combination of AFP and AAG resulted 
better sensitivity and accuracy compared with AFP 
examination alone.17 
AAG is not an invasive examination and the 
result can soon be obtained. The examination can 
be performed using usual technique in common 
laboratories. Compared with AFP examination, the 
AAG examination is cheaper with better sensitivity 
and accuracy. This study evaluated the best diagnostic 
cut off value of AAG in diagnosing HCC patients with 
liver cirrhosis, since majority (80%) of HCC patients 
had liver cirrhosis prior to HCC and one third of liver 
cirrhosis patients developed HCC in their life.18 It was 
just a small portion of patients got HCC without having 
liver cirrhosis. 
METHOD
This was a cross sectional diagnostic study 
conducted at Division of Hepatobiliary, Department 
of Internal Medicine, Cipto Mangunkusumo Hospital 
in January to October 2013. The study group consisted 
of HCC patients having liver cirrhosis and the control 
group consisted of liver cirrhosis patients without HCC 
in the medicine ward of General Hospital Dr. Cipto 
Mangunkusumo and Persahabatan Hospital, Jakarta. 
All subjects were taken consecutively until achieving 
sample size requirement with inclusion criteria as 
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follow: 1) Patient diagnosed with HCC with liver 
cirrhosis based on anamnesis, physical examination, 
laboratoryoratory examination and abdominal USG, 
abdominal CT with 3 phases contrast (liver biopsy 
was done if needed); 2) Patient diagnosed with liver 
cirrhosis without nodule based on anamnesis, physical 
examination, laboratoryoratory examination and 
abdominal USG; 3) First visit patient and have not 
been treated for HCC; 4) 17 years old and above; 5) 
willing to participate in the study. Exclusion criteria 
were: 1) Having other malignancy diseases such as 
colon tumor, lung tumor, pancreatic tumor, etc; 2) 
HCC patients without liver cirrhosis; 3) Having acute 
infection diseases, such as pneumonia, colitis, acute 
hepatitis, sepsis or HIV; 4) Undergoing corticosteroid 
treatment; 5) Having surgery or any trauma recently; 
6) Having cardiac myocard infarct recently. Minimal 
sample size was 46 subjects.
AAG examination result of all subjects were 
presented in the receiver operating characteristic 
(ROC) with area under the curve (AUC) and a table 
consisting several cut-off AAG value with each 
??????????????????????????????????????????????????????????
negative predictive value (NPV), positive likelihood 
ratio (PLR), and negative likelihood ratio (NLR). We 
then assessed the best AAG cut-off value to be aware 
of HCC and to diagnose HCC with liver cirrhosis.
Blood sample for AAG examination was collected 
from each subject by using 1 yellow cap serum 
separating tube. The 6 cc of blood sample was put 
in the room temperature for 30-45 minutes until it 
clotted. Sample was directly sent to the laboratory to 
be centrifuged (3000 rpm) for 15 minutes duration. 
Serum then was separated and put into 2 cups, 0.3 cc 
each (1 for sample, 1 for reserve). The cup then was 
labeled with subject’s name, date, type of examination 
prior to AAG examination. 
RESULTS
?????????????????????????????????????????????????
37 liver cirrhosis patients were included within the 
study period. All patients were 30 years and above, with 
the tendency of increasing in the number of patient as 
the age increased. Seventy two percent of HCC patients 
with liver cirrhosis were 50 years old and above. Most 
of the patients in each group had ascites and decreased 
serum albumin. The most common etiology in each 
group was chronic hepatitis B infection, 56% and 
67.6% respectively (Table 1). According to abdominal 
USG and 3 phases contrast abdominal CT, most of the 
HCC patients with liver cirrhosis had multiple nodules 
in both liver lobes (80%).
Table 1. Basic characteristic of patient
Variable
HCC + cirrhosis 
(study group)
n (%)
Cirrhosis
(control group)
n (%)
Sex
Male 23 (92) 21 (56.7)
Female 2 (8) 16 (43.3)
Age (year) 55.62 (+ 11.92)* 55,56 (+ 12.62)*
< 30 0 (0) 0 (0)
30 – 40 3 (12) 3 (8.1)
40 – 50 4 (16) 10 (27.1)
50 – 60 9 (36) 11 (29.7)
> 60 9 (36) 13 (35.2)
Physical examination
Ascites 15 (60) 20 (54.1)
Laboratory examination
Albumin (g/dL) 2.95 (+ 0.56)* 2.87 (+ 0.37)*
Total bilirubin (mg/dL) 1.87 (+ 0.96)* 1.54 (+ 0.66)*
HBsAg positive 14 (56) 25 (67.6)
Anti HCV positive 5 (20) 8 (21.6)
HBsAg & anti HCV 
negative
6 (24) 4 (10.8)
Total 25 (100) 37 (100)
HCC: hepatocellular carcinoma; HCV: hepatitis c virus *mean, SD
AAG result of each group was presented in Table 
2 and Figure 1.
Table 2. Median of AAG examination result in study group and 
control group
Variable
Study group
median (min-max)
Control group
median (min-max)
Alpha-1 acid glyco-
protein (mg/dL)
124,7 (48,1-291,4) 59,0 (19,0-218,5)
AAG: alpha-1 acid glycoprotein
Using ROC, the AUC for AAG examination to 
diagnose HCC was 81.44% with standard error 0.0548 
?????????????????????????????????????????????????????
Figure 1. Distribution of alpha-1 acid glycoprotein (AAG) 
examination result in study group and control group
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Figure 2. ROC of alpha-1 acid glycoprotein (AAG) result in 
study group
The incidence of HCC increased since 40 years old 
and above, mostly in patients older than 50 years old 
(72%). Mean age of the HCC patients with cirrhosis 
was 55.62 +? ?????? ?????? ?????????? ??????????? ???
????????????????????????????????????????????????????
showing highly increased of HCC incidence started 
40 years old and above, although there is a tendency 
recently of HCC incidence in younger age group of 
patients (40 to 60 years old).1,19,20 
In this study, there was a different in the composition 
of male and female between the two groups, but the 
mean age of each group was not highly different. The 
mean age in the study group was 55.62 + 11.92 years 
old. Physical and laboratoryoratory examination of 
both groups showed most of the patient had poor liver 
function. According to Child-Pugh score, most patients 
in this study were Child-Pugh score B, having ascitesin 
each group (605 and 54.1%) and decreased serum 
albumin (less than 3 g/dL). Most common etiology 
in this study was chronic hepatitis B virus infection 
(56%), and chronic hepatitis C virus infection was 
just 20%. There was various etiology of HCC in each 
country in the same region.21 
Chronic hepatitis B virus infection was the most 
common etiology of HCC in China, Taiwan, Korea, 
Thailand, India, Vietnam, Turkey, and Myanmar (50-
85%). Especially in China, most off HCC etiology 
was chronic hepatitis B virus infection with odds ratio 
12.45, and the odds ratio of chronic hepatitis C virus 
infection was just 4.28.3,5 Moreover, the incidence of 
hepatitis B related HCC increased linearly from 1960 to 
2005 in Australia in immigrant population originating 
????????????????????????????????????????????????????????????? ???????????
AAG cut-off  
(mg/dL)
Sensitivity
(%)
??????????
(%)
???
(%)
???
(%)
??? NLR
20.7 100.0 2.78 40.98 100.00 1.03 0.00
30.8 100.0 11.11 43.10 100.00 1.13 0.00
40.1 100.0 25.00 47.16 100.00 1.33 0.00
54.3 96.0 44.44 53.33 94.11 1.73 0.09
61.3 92.0 58.33 59.00 91.00 2.21 0.14
74.3 88.0 66.67 57.89 87.50 2.64 0.18
78.6 80.0 73.0 64.66 84.37 2.88 0.28
82.6 72.0 72.22 64.28 79.41 2.59 0.39
93.8 68.0 80.56 70.83 78.94 3.49 0.39
106.1 64.0 83.33 72.72 77.50 3.84 0.43
117.5 56.0 86.11 72.22 72.72 4.03 0.51
129.6 48.0 88.89 73.33 70.21 4.32 0.58
136.2 44.0 91.67 79.00 71.00 5.28 0.61
146.7 32.0 91.67 72.72 66.66 3.84 0.74
175.1 24.0 91.67 66.66 64.15 2.88 0.83
190.6 16.0 91.67 57.14 61.81 1.92 0.92
207.1 12.0 97.22 75.00 62.06 4.32 0.90
291.4 4.0 100.00 100.00 60.65 0.96
AAG: alpha-1 acid glycoprotein; PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio
To get the best cut-off value of AAG, we assessed 
???? ????????????? ???????????? ????????? ??????????? ??????
(PPV), negative predictive value (NPV), positive 
likelihood ratio (PLR), negative likelihood ratio (NLR) 
from each cut-off (Table 3).
DISCUSSION
There were 92% male in study group. Incidence in 
male was 8 times greater than female. Similar result 
was reported by Lehman et. al. from Egypt with 80% 
male19 This result is different with the incidence of 
??????? ???????????????????????? ??????????????????
with male to female ratio was 3 : 1.1,5 Ajayi et al from 
Nigeria also reported male to female ratio in HCC was 
2.31 : 1. In Japan, however, the incidence of HCC in 
male was almost the same with female.5,20
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?????????? ??????? ???????6 In Japan and Pakistan, 
chronic hepatitis C virus infection was the most 
common etiology of HCC, ranging from 45% to 80%. 
In Japan, 79% of HCC patients were due to chronic 
hepatitis C virus infection and only 11% were due to 
chronic hepatitis B virus infection.5 In Europe, the most 
common etiology of HCC, as reported in Germany, 
Austria, Sewdia, Belgia, England, was neither chronic 
hepatitis B infection nor chronic hepatitis C infection 
(50-80%).21 Only Greek reported chronic hepatitis B 
virus infection as the most common etiology of HCC 
(55%). Italy and Spain reported chronic hepatitis C 
virus infection as the most common etiology of HCC 
(40-50%).21
In America, almost the same with Europe region, 
most of the HCC cases were not due to chronic hepatitis 
B or C virus infection (65%). This was due to the low 
prevalence of chronic hepatitis B and C virus infection 
in that region, high rate of alcohol consumption, and 
increased prevalence of overweight and obesity which 
was associated with liver cirrhosis in America and 
Europe.22,23 The low prevalence of chronic hepatitis 
B virus infection in Europe and America was due 
to the success of universal vaccination program in 
child and adult.24 And the low prevalence of chronic 
hepatitis C virus infection was due to good preventing 
program, early diagnosis, and accessibility to the good 
standard treatment of hepatitis C.24,25 The good socio-
economic level and insurance system also contributed 
to this result. In contrast, culture in the community 
with high alcoholic consumption, high prevalence of 
obesity, overweight and hypertension contributed as 
the etiology of HCC in that region. 
The distribution of AAG laboratory examination 
in each groups were not normal. In the study group, 
there was 1 subject having result above other subjects’ 
result. In the control group, there were 2 subjects 
having extremely high result above others’. Although 
totally there were 3 extreme AAG examination results, 
we did not take them out and still included them in the 
statistics calculation. We assumed that there was no 
?????????????????????????????????????????????????? ???
laboratory examination result.
The median of AAG laboratory examination result 
in the study group was 124.7 mg/dL, which was above 
normal. The median of AAG laboratory examination 
result in the control group was within normal reference 
value, 59.0 mg/dL. This result showed that most subjects 
in the study group had AAG laboratory examination 
result above normal. This was in coherent with the 
previous study showing around 80% HCC patients had 
increased of AAG and only 20% liver cirrhosis patients 
had increased of AAG. Majority of subjects in the study 
group had multiple nodules (80%). One subject had 2 
nodules (4%), 4 four subjects had single nodules (16%) 
with diameter greater than 5 cm. Using Barcelona Clinic 
Liver Cancer (BCLC) criteria, most subjects were in 
the intermediate stadium (B) or higher. Therefore, the 
treatment more on palliative therapy.24
One of the parameter to assess the suitability of an 
examination to be used as a diagnostic examination 
is the AUC value of the ROC. Theoritically, the 
AUC value is between 50% and 100%. Based on 
??????????????? ???????????? ??????? ??? ???????????????
in clarifying the diagnostic power of an examination 
as follow: very weak (AUC 50 - 60%), weak (60% - 
70%), intermediated (70% - 80%), good (80% - 90%), 
very good (90% - 100%).25 The AUC in our study was 
81.44%, showing that AAG laboratory examination 
was statistically categorized as a good examination 
for diagnostic examination of HCC in liver cirrhosis.
We evaluated the best AAG laboratory examination 
???????? ??????????????????? ??????????????????????????
?????????? ??????????????????????????????? ?????????????
the PPV, LPR, and sensitivity. Based on several cut-off 
????????????????????????????????? ?????????????????????
136.2 mg/dL until 291.4 mg/dL (91.67% until 100%). 
Within that values, the best PPV and LPR was at 136.2 
mg/dL (79% and 5.28, respectively). The sensitivity 
value was also the best within that range, which was 
44.0%. Therefore, the best AAG value in diagnosing 
HCC in patients with liver cirrhosis was 136.2 mg/
dL. To make it easier in daily clinical practice, it was 
rounded to 136 mg/dL. The daily clinical application 
of this study was if a liver cirrhosis patient with liver 
nodule had AAG laboratory examination < 136 mg/
dL, the patient had 91.67% probability having no 
HCC. But, if the AAG laboratory examination was > 
136 mg/dL, the patient had 79% probability having 
?????????????????????????????????????????????????
in liver cirrhosis, we can use 291 mg/dL as the cut-off. 
If the AAG was > 291 mg/dL, the patient had very 
??????????????????????????? ??? ?????????????????????
We also evaluated the possibility using AAG 
laboratory examination to be aware of HCC in liver 
??????????? ??? ???? ??????? ???? ??????? ??? ?????? ???????
through abdominal USG in liver cirrhosis patient let us 
aware of HCC possibility. Other method to be aware 
of HCC in liver cirrhosis patient was checking AAG 
in liver cirrhosis patients. If the result was above the 
cut-off value, abdominal USG should be done to look 
for liver nodule. 
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From the various cut-off values to be aware of 
HCC in liver cirrhosis (Table 5), the sensitivity was 
good between 78.6 mg/dL and 20.7 mg/dL (80% and 
100%, respectively). Within the range, 61.3 mg/dl had 
??????????????????????????????????????????????????????????
PPV, LPR values were just 58.33%, 59%, and 2.21, 
respectively). The sensitivity value at 78.6 mg/dl 
???? ?????? ?????????????? ??????? ???? ???? ????????????
PPV, LPR values were better (72.22%, 64% and 2.88, 
respectively). In comparison of those two cut-offs, 61.3 
mg/dL was the best cut-off since we needed greater 
sensitivity (> 90%) to be aware of a disease (HCC 
??? ?????? ??????????? ????????? ??? ???? ?????? ????????????
PPV, LPR values. To make it simpler in daily clinical 
practice, the best cut-off value to be aware of HCC in 
liver cirrhosis was 61 mg/dL. In clinical application, for 
a cirrhosis patient with liver nodule having AAG less 
than 61 mg/dL, the liver nodule highly probable (91%) 
was not HCC (NPV in 61 mg/dL was 91%); therefore, 
the nodule can be managed as non HCC nodule in liver 
cirrhosis. However, if the AAG was greater than 61 
mg/dL, 92% HCC nodule would be diagnosed at that 
cut-off and 59% was true HCC. Hence, other additional 
examinations should be performed to ensured the HCC, 
such as AFP.
The AAG examination can be used to be aware 
of and diagnose HCC in liver cirrhosis patients with 
liver nodule, especially in the patients who are not 
able to undergo 3 phases contrast abdominal CT or 
liver biopsy. The AAG might also serves as alternative 
biomarker examination of AFP with lower cost, faster 
gained result, and simpler examination which can be 
done in ordinary laboratory.
CONCLUSION
The best cut-off value of AAG to be aware of HCC 
in liver cirrhosis was 61 mg/dL and the best cut-off 
value of AAG to diagnose HCC in liver cirrhosis 
was 136 mg/dL. AAG can be used as an alternative 
biomarker to be aware of and to diagnose HCC in 
liver cirrhosis with liver nodule greater than 5 cm, 
no infection, no other malignancies, not recently 
got heart attack or any surgical procedures. Further 
studies in evaluating AAG as diagnostic biomarker 
in HCC patients without liver cirrhosis, HCC patients 
with different size of nodules, and HCC patients with 
different etiologies should be performed.
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